Company Overview and News


Add MRK
to your dashboard

Headline News

BioLineRx/Roche Scan BL-8040-Tecentriq for Gastric Cancer

16h zacks
BioLineRx Ltd. (BLRX - Free Report) announced that its partner Genentech, a member of Roche Holding AG (RHHBY - Free Report) , has initiated a phase Ib/II study to evaluate its lead pipeline candidate, BL-8040, in combination with Roche’s Tecentriq (atezolizumab) for treating patients with gastric cancer. (86-0)

Tracking Ken Fisher's Fisher Asset Management Portfolio - Q3 2017 Update

2017-10-20 seekingalpha
Alibaba Group Holdings, Amazon.com, Visa Inc., Apple Inc., and Johnson & Johnson are the largest five individual stock positions. (1097-1)

AstraZeneca's sNDA for Two Cancer Drugs Gets Priority Review

2017-10-19 zacks
AstraZeneca, plc (AZN - Free Report) and partner Merck (MRK - Free Report) announced that the FDA has granted priority review to its supplemental New Drug Application (sNDA) for Lynparza. With this sNDA, AstraZeneca and Merck are looking to expand the label of Lynparza, presently marketed for advanced ovarian cancer, to an advanced breast cancer indication. (83-0)

Why Are These 6 Dow Stocks Fairly Valued?: Part 4 Of 5

2017-10-19 seekingalpha
The Dow Jones Industrial Average is at an all-time high, but here are six that are fairly valued. (199-0)

Your Daily Pharma Scoop: Gilead's Brave New World, AZN's Lynparza SNDA, RXDX Entrectinib Shows Positive Results

2017-10-19 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (701-3)

Market Is Not Waiting For Tax Reform - Cramer's Mad Money (10/18/17)

2017-10-19 seekingalpha
US Treasury Secretary Steven Mnuchin said that the tax reform is baked into the market and if it doesn't go through, it will impact stocks negatively. Cramer thinks otherwise. "Look, I appreciate he's trying to get Congress motivated, but just on the facts, I think he's quite wrong. The truth is, most executives don't believe tax reform is coming. It's simply not integral to this market. Yes, they've lost faith," he said. (156-1)

A KISS Dividend Strategy Worth 15% A Year

2017-10-19 seekingalpha
Quantitative investing aims at making systematic investment decisions based on hard data. Quantitative models make the investment process: (42-0)

Pricing Pressure, Competition Remain Headwinds for Pharma Stocks

2017-10-18 zacks
While the drug pricing issue no longer remains a major headwind for pharma and biotech stocks, it will nevertheless remain a headline risk until the Trump administration comes out with a policy for controlling drug prices. The sector, previously a Wall Street favorite, was hit hard by political rhetoric and increasing media and public focus on the high prices of drugs. With the drug pricing controversy gaining steam since September 2015, companies like Valeant saw their share prices plunging as they found themselves in the midst of the controversy. (211-0)

What to Expect from Big Pharmas After J&J's Solid Q3 Results?

2017-10-18 zacks
Johnson & Johnson (JNJ - Free Report) was the first large-cap pharma stock to report its earnings results for this season on Oct 17. J&J beat the Zacks Consensus Estimate for both earnings and revenues in the third quarter and also raised its 2017 sales and profit outlook. Shares of J&J were up more than 3% on Tuesday. (23-0)

A Bit About Biopharma Investing

2017-10-18 seekingalpha
Well, as predicted here (and many other places), Merck (NYSE:MRK) announced October 11 that they are indeed not going to try to seek approval for their CETP inhibitor, anacetrapib. That’s despite an ostensibly positive Phase III trial, but it apparently wasn’t positive enough to take the risk of bringing this drug before the FDA (or to the market). (3-0)

5 Blue-Chip Stocks That "Dow 23,000" Left in the Dust | InvestorPlace

2017-10-18 investorplace
The bulls are parading around Wall Street on Wednesday as better-than-expected earnings from International Business Machines Corp. (NYSE:IBM) sent shares soaring to their best gain in eight years — never mind the 22nd consecutive decline in revenues. IBM’s success pushed the Dow Jones Industrial Average definitively up and over the 23,000-level that was teased on Tuesday. (111-0)

The Vision Is Clear: Listen To Merck And Invest In Microcap KalVista Pharmaceuticals

2017-10-18 seekingalpha
KalVista remains under $100M market cap despite huge partnership with Merck which included $37M upfront cash and 10% ownership stake (366-3)

Only 16 Of 61 Are 'Safer' Dividend Healthcare Dogs For October

2017-10-18 seekingalpha
Top "safer" dividend Healthcare dog, GSK's 16.2% net gain was 58% more than MRK's 10.4% second place effort, and 100% over PFE's fourth place result per analyst targets 10/13/17. (91-0)

Healthcare Dogfight: Owens & Minor Edges GlaxoSmithKline As Top Broker Pick For Gains In October

2017-10-18 seekingalpha
The Healthcare sector is composed of ten component industries. The top 50 firms selected by yield for this writing represented all of those industries. (174-0)

Top Analyst Upgrades and Downgrades: Chevron, Chipotle, Exxon, Goldman Sachs, GoPro, IBM, Merck, Petrobras, UnitedHealth, Visa, Zynga and More

2017-10-18 247wallst
Stocks hit new highs this week, and Wednesday looks to be the day that the Dow Jones Industrial Average will vault through 23,000. Dow futures were up 91 points and S&P futures were up four points. The trend that has dominated continually and often surprisingly for more than five years is that investors keep finding new reasons to buy their favorite stocks after every major sell-off. Those same investors are also hunting for new investing and trading ideas with their capital. (243-0)

Exploring AstraZeneca's Two-Prong Assault On Lung Cancer

2017-10-18 seekingalpha
AstraZeneca has made huge moves in the 2nd half of 2017, particularly with respect to lung cancer therapy (145-0)

Dynavax Reports More Good News

2017-10-17 seekingalpha
Sales leadership and initial supply are in place and company is ready to launch, preferably with a licensing partner. (45-0)

J&J (JNJ) Beats on Q3 Earnings, Actelion Buyout Drives Sales

2017-10-17 zacks
Johnson & Johnson (JNJ - Free Report) reported better-than-expected third-quarter 2017 results, beating the Zacks Consensus Estimate for both earnings and sales. The drug and consumer products giant raised its 2017 sales and profit outlook, which sent shares up 1.5% in pre-market trading. (81-0)

Bristol-Myers Gets Priority Review for Opdivo Label Expansion

2017-10-17 zacks
Bristol-Myers Squibb Company (BMY - Free Report) announced that that the FDA has granted priority review to the supplemental Biologics License Application (sBLA) for the label expansion of Opdivo. (113-0)

Merck's Risk/Reward Is Compelling

2017-10-16 seekingalpha
DCF analysis reveals upside potential of around 16% based on a perpetuity growth method or 15% based on an EBITDA exit multiple method. (113-0)

Merck Pulls The Plug On Cholesterol Drug

2017-10-16 seekingalpha
Phase 3 data was lackluster at best, which was a wise decision for Merck to not file for its CETP inhibitor Anacetrapib to the FDA. (75-0)

Sanofi: Upward Trajectory In 2017

2017-10-16 seekingalpha
The vaccines segment is also proving to be a promising opportunity for the company in 2017. (67-0)

Roche And Allergan: Approaches To Alzheimer's

2017-10-13 seekingalpha
There has been a lot in the press during the past year that pertains to Alzheimer’s disease. While Hillary Clinton’s second presidential campaign made it an issue, new data that is not supportive of formerly viable hypotheses are important. Eli Lilly and Company (LLY) has spent a lot of money attempting to treat Alzheimer’s, since well before Clinton’s candidacy. Similar to other firms, most of Lilly’s effort has been directed at a misfolded protein known as amyloid plaque (Aβ). (204-0)

Are These The 6 Best Stocks In The Dow Jones Industrial Average? - Part 3 Of 5

2017-10-13 seekingalpha
The Dow Jones Industrial Average is at all-time highs, but how many of the 30 Dow stocks are overvalued? (299-0)

Cancer Space Update: Lung & Breast Cancer Studies in Focus

2017-10-13 zacks
Major news in the cancer segment this week was the failure of Eli Lilly and Company’s (LLY - Free Report) newly approved breast cancer drug Verzenio in a pivotal lung cancer study. With this latest failure, Lilly joins the list of large pharma companies who have failed in their respective lung cancer pivotal studies in the recent past. However, Verzenio was granted priority review status as first-line treatment for breast cancer. (151-0)

CUSIP: 58933Y955